CARD9 attenuates Aβ pathology and modifies microglial responses in an Alzheimer's disease mouse model.

ABSTRACT: Recent advances have highlighted the importance of several innate immune receptors expressed by microglia in Alzheimer's disease (AD). In particular, mounting evidence from AD patients and experimental models indicates pivotal roles for TREM2, CD33, and CD22 in neurodegenerative disease progression. While there is growing interest in targeting these microglial receptors to treat AD, we still lack knowledge of the downstream signaling molecules used by these receptors to orchestrate immune responses in AD. Notably, TREM2, CD33, and CD22 have been described to influence signaling associated with the intracellular adaptor molecule CARD9 to mount downstream immune responses outside of the brain. However, the role of CARD9 in AD remains poorly understood. Here, we show that genetic ablation of

SUBMITTER: Ennerfelt H 

PROVIDER: S-EPMC10268238 | biostudies-literature | 2023 Jun

REPOSITORIES: biostudies-literature